Biomeditsina va amaliyot jurnali, 2022 №2
Subject of the article
POLYMORPHISM OF MDR1 GENE – RESISTANCE MARKERS TO CHEMOTHERAPY AT ONCOLOGICAL DISEASES (243-248)
Authors
Kadirova Dilbar, Alimhodjaeva Lola, Ibragimov Adil.
Institution
Doctor of Biological Sciences, Associate Professor Institute of biophysics and biochemistry Doctor of Medical Sciences, Associate Professor Republican specialized scientific and practical medical center of oncology and radiology Doctor of Biological Sciences Tashkent Institute of Vaccine and Serum
Abstract
ANNOTATION Purpose: Determination of a personal genotype of drug stability of cancer patients according to polymorphic marker 3435T MDR1 gene to predict individual chemotherapy regime. Methods: During the implementation of studies, DNA samples obtained from peripheral blood leukocytes of patients suffering from breast cancer (BC) (80 patients) and NHL (75 patients) were used. Results: Identifying genetic features in patients in the polymorphic marker C3435T gene MDR1 allows you to predict the nature of the pharmacological response, which makes it possible to improve the efficiency and safety of drug use - dose, the multiplicity of administration, the path of administration, the replacement of medicines and the real possibility of individualization of pharmacotherapy with various oncological diseases. The frequency of occurrence of genotypes among healthy donors and oncological patients with diagnosis of breast cancer and non-Hodgkin's lymphoma was carried out. Conclusions: It has been shown that the frequency of occurrence of homozygous TT genotype in breast cancer and Non-Hodgkin's lymphoma is higher than the occurrence of CC and CT genotypes.
Key words
Keywords: DNA, polymorphism, MDR1, C3435T, BC, NHL, Cancer.
Literature
1. Ambudkar S.V., Dey S., Hrycyna C.A. Biochemical, cellular, and pharmacological aspects of the multidrug transporter//Annu. Rev. Pharmacol. Toxicol.- 2011. - V. 39. - P. 361-398 2. Al-Mahayri Z.N.,Patrinos G.P. , Ali1 B.R. Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy. Front. Pharmacol., 2020. Vol. 11. P.1-16. 3. Rangel G. J., , Martínez M.O., Flores R.C, Saldana H.B. C3435T polymorphism in the MDR1 gene and breast cancer risk in northeastern Mexico. Int J Clin Exp Pathol. 2018. Vol. 11. N.2. P. 904-909. 4. Mekkey A. M., Abed A. S., Mohammed Z., Jawad N. N., Saad A. Molecular effect MDR1(C3435T) gene polymorphism on leukemia patients in Babylon province, Iraq. J. Annals of Tropical Medicine and Public Health 2020. Vol. 22. N.9. P.15-19. 5. Petryszyn P., Dudkowiak R., Gruca A., Tarnawska J.E., Cierniakowski P., C3435T Polymorphism of the ABCB1 Gene in Polish Patients with Inflammatory Bowel Disease: A Case–Control and Meta-Analysis Study. Genes 2021. N 12. P. 1-13 6. Lu S., Zhu X., Li W., Chen H., Zhou D. Influence of Methylenetetrahydrofolate Reductase C677T and A1298C Polymorphism on High-Dose Methotrexate-Related Toxicities in Pediatric Non-Hodgkin Lymphoma Patients. Front. Oncol. 2021. Vol. 11. P. 1-9. 7. Non-Hodgkin's Lymphoma Causes, Symptoms, and Treatment. Knott L., Willacy H. J.Oncologyyy. 2021. P. 1-12 8. Rangel G. J., , Martínez M.O., Flores R.C, Saldana H.B. C3435T polymorphism in the MDR1 gene and breast cancer risk in northeastern Mexico. Int J Clin Exp Pathol. 2018. Vol. 11. N.2. P. 904-909.